Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTXNASDAQ:MBRXNASDAQ:MNPRNASDAQ:VTGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.23-3.9%$1.29$0.85▼$4.40$39.42M0.2531,229 shs42,866 shsMBRXMoleculin Biotech$0.69+4.2%$0.91$0.40▼$4.90$9.74M1.561.53 million shs431,500 shsMNPRMonopar Therapeutics$34.65+0.4%$36.89$1.72▼$54.30$211.89M0.99358,561 shs11,648 shsVTGNVistagen Therapeutics$2.36-1.3%$2.29$1.90▼$4.21$68.11M0.7171,703 shs130,428 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics+2.00%-5.56%+1.18%+37.10%-49.40%MBRXMoleculin Biotech-1.19%-21.20%-36.95%-47.46%-84.64%MNPRMonopar Therapeutics-0.35%+7.47%-12.99%+11.68%+791.04%VTGNVistagen Therapeutics+2.14%0.00%+6.70%-14.34%-35.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMBRXMoleculin Biotech3.1508 of 5 stars3.55.00.00.02.70.01.3MNPRMonopar Therapeutics3.3018 of 5 stars3.45.00.00.03.72.50.0VTGNVistagen Therapeutics1.1872 of 5 stars0.02.00.00.03.31.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 0.00N/AN/AN/AMBRXMoleculin Biotech 3.00Buy$4.00480.13% UpsideMNPRMonopar Therapeutics 2.75Moderate Buy$55.3359.69% UpsideVTGNVistagen Therapeutics 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest MBRX, MNPR, AKTX, and VTGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$4.004/2/2025MNPRMonopar TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/1/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/25/2025MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$4.003/24/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/19/2025MNPRMonopar TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$76.00(Data available from 6/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A($0.03) per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A$11.70 per shareN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$1.88 per shareN/AVTGNVistagen Therapeutics$698K97.58N/AN/A$2.81 per share0.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$10.01MN/A0.00∞N/AN/AN/AN/A8/18/2025 (Estimated)MBRXMoleculin Biotech-$29.77MN/A0.00N/AN/AN/A-157.44%-97.16%8/4/2025 (Estimated)MNPRMonopar Therapeutics-$8.40M-$3.48N/AN/AN/AN/A-107.21%-87.57%8/8/2025 (Estimated)VTGNVistagen Therapeutics-$29.36M-$1.48N/AN/AN/A-6,777.08%-48.12%-43.80%8/11/2025 (Estimated)Latest MBRX, MNPR, AKTX, and VTGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MBRXMoleculin Biotech-$0.71-$0.69+$0.02-$0.69N/AN/A5/13/2025Q1 2025MNPRMonopar Therapeutics-$0.65-$0.38+$0.27-$0.38N/AN/A3/31/2025Q4 2024MNPRMonopar Therapeutics-$0.36-$2.23-$1.87-$2.23N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/AVTGNVistagen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.290.29MBRXMoleculin BiotechN/A2.082.08MNPRMonopar TherapeuticsN/A5.415.41VTGNVistagen TherapeuticsN/A9.359.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%MBRXMoleculin Biotech15.52%MNPRMonopar Therapeutics1.83%VTGNVistagen Therapeutics78.39%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.90%MBRXMoleculin Biotech1.90%MNPRMonopar Therapeutics20.50%VTGNVistagen Therapeutics1.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics932.18 million16.25 millionNot OptionableMBRXMoleculin Biotech2014.13 million3.86 millionNot OptionableMNPRMonopar Therapeutics106.12 million3.97 millionNot OptionableVTGNVistagen Therapeutics4028.86 million28.49 millionOptionableMBRX, MNPR, AKTX, and VTGN HeadlinesRecent News About These CompaniesVistagen Therapeutics (VTGN) to Release Earnings on TuesdayJune 3, 2025 | marketbeat.comVistagen Therapeutics (NASDAQ:VTGN) Shares Pass Above 50 Day Moving Average - Should You Sell?May 28, 2025 | marketbeat.comVistagen to Present at the 2025 American Society of Clinical Psychopharmacology ConferenceMay 23, 2025 | businesswire.comVistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 ConferenceApril 17, 2025 | businesswire.comWhy Vistagen Therapeutics, Inc.’s (VTGN) Stock Is Down 10.10%April 8, 2025 | aaii.comVistaGen at Stifel 2025: Pioneering Acute SAD TreatmentMarch 20, 2025 | investing.comVistagen to Present at the 2025 Anxiety and Depression Association ConferenceMarch 19, 2025 | businesswire.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call TranscriptFebruary 15, 2025 | msn.comVistaGen’s Earnings Call: Progress and ChallengesFebruary 14, 2025 | tipranks.comVistagen: Pherine Candidate Proof Of Concept Continues With Fifth IndicationFebruary 14, 2025 | seekingalpha.comStemPoint Capital LP's Strategic Acquisition of Vistagen Therapeutics Inc SharesFebruary 14, 2025 | gurufocus.comVistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ...February 14, 2025 | gurufocus.comQ3 2025 Vistagen Therapeutics Inc Earnings Call TranscriptFebruary 14, 2025 | gurufocus.comVistagen advances Phase 3 SAD trials with 2025 data readout targetFebruary 13, 2025 | msn.comVistagen reports Q3 EPS (46c) vs (22c) last yearFebruary 13, 2025 | markets.businessinsider.comEarnings call transcript: VistaGen Therapeutics reports Q3 FY2025 net lossFebruary 13, 2025 | msn.comVistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call TranscriptFebruary 13, 2025 | seekingalpha.comVistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue EstimatesFebruary 13, 2025 | zacks.comVistagen Therapeutics Inc (VTGN) Q3 FY2025 Earnings: EPS of -$0. ...February 13, 2025 | gurufocus.comEarnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2025 ResultFebruary 12, 2025 | gurufocus.comVistagen granted USPTO patent for AV-101 to treat neuropathic painFebruary 6, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMBRX, MNPR, AKTX, and VTGN Company DescriptionsAkari Therapeutics NASDAQ:AKTX$1.23 -0.05 (-3.92%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Moleculin Biotech NASDAQ:MBRX$0.69 +0.03 (+4.15%) Closing price 04:00 PM EasternExtended Trading$0.68 -0.01 (-1.96%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.Monopar Therapeutics NASDAQ:MNPR$34.65 +0.14 (+0.41%) Closing price 04:00 PM EasternExtended Trading$34.24 -0.41 (-1.17%) As of 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Vistagen Therapeutics NASDAQ:VTGN$2.36 -0.03 (-1.26%) Closing price 04:00 PM EasternExtended Trading$2.44 +0.08 (+3.39%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY GitLab: Buy It Low While You Still Can—Higher Prices Are Coming RKLB Breakout Fails Near Highs: Should Investors Be Concerned? Amazon Is on Track to Hit a Critical Level: Watch Out Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal Nintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive? Will Warner Bros. Discovery’s Split Produce Double the Upside? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
